Department of Clinical Sciences and Community Health, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy; Experimental Laboratory of Immunological and Rheumatologic Researches, IRCCS Istituto Auxologico Italiano, Via Zucchi 18, 20095 Cusano Milanino, Milan, Italy.
Experimental Laboratory of Immunological and Rheumatologic Researches, IRCCS Istituto Auxologico Italiano, Via Zucchi 18, 20095 Cusano Milanino, Milan, Italy.
J Autoimmun. 2018 Jun;90:76-83. doi: 10.1016/j.jaut.2018.02.002. Epub 2018 Feb 14.
Antibodies against β2 glycoprotein I (anti-β2GPI) have been identified as the main pathogenic autoantibody subset in anti-phospholipid syndrome (APS); the most relevant epitope is a cryptic and conformation-dependent structure on β2GPI domain (D) 1. Anti-β2GPI domain profiling has been investigated in thrombotic APS, leading to the identification of antibodies targeting D1 as the main subpopulation. In contrast, scarce attention has been paid to obstetric APS, hence this study aimed at characterizing the domain reactivity with regards to pregnancy morbidity (PM). To this end, 135 women with persistently positive, medium/high titre anti-β2GPI IgG, without any associated systemic autoimmune diseases and at least one previous pregnancy were included: 27 asymptomatic carriers; 53 women with obstetric APS; 20 women with thrombotic APS; and 35 women with both thrombotic and obstetric complications. Anti-D1 and anti-D4/5 antibodies were tested using a chemiluminescent immunoassay and a research ELISA assay, respectively (QUANTA Flash β2GPI Domain 1 IgG and QUANTA Lite β2GPI D4/5 IgG, Inova Diagnostics). Positivity for anti-D1 antibodies, but not anti-D4/5 antibodies, was differently distributed across the 4 subgroups of patients (p < 0.0001) and significantly correlated with thrombosis (χ2 = 17.28, p < 0.0001) and PM (χ2 = 4.28, p = 0.039). Patients with triple positivity for anti-phospholipid antibodies displayed higher anti-D1 titres and lower anti-D4/5 titres compared to women with one or two positive tests (p < 0.0001 and p = 0.005, respectively). Reactivity against D1 was identified as a predictor for PM (OR 2.4, 95% confidence interval [CI] 1.2-5.0, p = 0.017); in particular, anti-D1 antibodies were predictive of late PM, conveying an odds ratio of 7.3 (95% CI 2.1-25.5, p = 0.022). Positivity for anti-D1 antibodies was not associated with early pregnancy loss. Anti-D4/5 antibodies were not associated with clinical APS manifestations. As a whole, our data suggest that anti-D1 antibodies are significantly associated not only with thrombosis, but also with late PM, while positive anti-D4/5 antibodies are not predictive of thrombosis or PM.
抗β2 糖蛋白 I(抗-β2GPI)抗体已被确定为抗磷脂综合征(APS)中主要的致病性自身抗体亚群;最相关的表位是β2GPI 结构域(D)1 上的隐蔽且构象依赖性结构。在血栓性 APS 中已经研究了抗-β2GPI 结构域的特征,导致了针对 D1 的抗体作为主要亚群的鉴定。相比之下,对产科 APS 的关注较少,因此本研究旨在针对妊娠发病率(PM)来描述结构域反应性。为此,纳入了 135 名持续存在高/中滴度抗-β2GPI IgG、无任何相关系统性自身免疫性疾病且至少有一次既往妊娠的患者:27 名无症状携带者;53 名产科 APS 患者;20 名血栓性 APS 患者;和 35 名既有血栓又有产科并发症的患者。使用化学发光免疫分析和研究酶联免疫吸附试验分别检测抗-D1 和抗-D4/5 抗体(QUANTA Flash β2GPI 结构域 1 IgG 和 QUANTA Lite β2GPI D4/5 IgG,Inova Diagnostics)。抗-D1 抗体的阳性率,但不是抗-D4/5 抗体的阳性率,在 4 组患者中分布不同(p<0.0001),与血栓形成(χ2=17.28,p<0.0001)和 PM(χ2=4.28,p=0.039)显著相关。抗磷脂抗体三联阳性的患者的抗-D1 滴度更高,抗-D4/5 滴度更低,与仅有一项或两项阳性检测的患者相比(p<0.0001 和 p=0.005)。抗-D1 反应性被确定为 PM 的预测因子(OR 2.4,95%置信区间[CI] 1.2-5.0,p=0.017);特别是,抗-D1 抗体预测晚期 PM,比值比为 7.3(95%CI 2.1-25.5,p=0.022)。抗-D1 抗体的阳性与早期妊娠丢失无关。抗-D4/5 抗体与临床 APS 表现无关。总的来说,我们的数据表明,抗-D1 抗体不仅与血栓形成显著相关,而且与晚期 PM 也显著相关,而阳性的抗-D4/5 抗体不能预测血栓形成或 PM。